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Abstract
Background: Discordance in hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) status
between primary tumors and metastatic sites for breast cancer is well established. However, it is uncertain which
patient-related factors lead to biopsy when metastases are suspected and whether having a biopsy impacts
survival.
Methods: The medical charts of metastatic breast cancer (MBC) patients diagnosed January 2000-August 2014 were
retrospectively reviewed. A biopsy was defined as a procedure where tissue was obtained and assessed for both HR
and HER2. Both bivariate and multivariate analyses were performed to assess patient characteristics related to
biopsy and whether having a biopsy was associated with improved survival.
Results: Of 409 patients suspected of having MBC, 165 (40%) had a biopsy, and 34% of these had discordant HR or
HER2 status when compared to the initial diagnosis. In multivariate analysis, having a biopsy was associated with:
recurrence in years 2010–2014, disease-free interval of > =3 years, stage 0-IIA at presentation, suspected locoregional
recurrence, being HR+/HER2-, or missing HR/HER2 at diagnosis. A similar multivariate analysis revealed that having a
biopsy was associated with improved survival (HR = 0.67, p = 0.002). The association of biopsy and improved survival
was noted in specific subgroups: patients with missing HR and HER2 data at initial diagnosis (p = 0.001), those without
metastases in liver, lung or brain (p = 0.001), and being younger than 70 years old at recurrence (p < 0.001).
Conclusions: Specific clinical factors were associated with biopsy at the time of suspected recurrence. Having a biopsy
was associated with reduced mortality.
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Background
Breast cancer is the most common cancer among
women in the United States, and it is estimated that
246,660 new cancer cases will be diagnosed in 2016 [1].
Despite recent progress in diagnostic and therapeutic
approaches of early breast cancer, many patients develop
metastases, resulting in about 40,000 deaths annually.
Systemic treatment in metastatic breast cancer (MBC),
as in early stage breast cancer, is chosen on the basis of
estrogen receptor (ER) and progesterone receptor (PR)
status and overexpression/amplification of the human
epidermal growth factor receptor 2 (HER2). In addition,
other factors are routinely used for therapy decisions,
such as disease-free interval, site(s) of relapse, and num-
ber of metastases [2, 3].
Discordance in hormone receptors and HER2 status
between the primary tumor and the metastatic lesion is
well documented [4]. A recent review demonstrated a
large range of receptor discordance with ER, PR and
HER2 discordance of 6–40%, 21–41% and 1–43%, re-
spectively [5]. In addition, a meta-analysis of 48 studies,
in which 4200, 2739, and 2987 tumors were evaluated
for ER, PR and HER2 discordance, respectively, showed
a discordance range of 8–23% [6]. The reasons for
discordance may relate to changes in tumor biology
between the initial tumor and the metastatic lesion biop-
sied, heterogeneity within the tumor itself, and/or imper-
fect accuracy and reproducibility of assays, although the
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relative contribution of each of these factors to the overall
discordance rate is unclear. The unequivocal recommenda-
tions for biopsy when metastases are suspected are: solitary
metastasis, unusual clinical course, and research [7]. The
existent discordance between the primary tumor and recur-
rent metastasis in ER, PR and HER2 status in portions of
tumors has been demonstrated in many studies [5, 8].
The Advanced Breast Cancer (ABC) consensus guide-
lines recommend biopsying a metastatic lesion, if easily
accessible, and confirming the diagnosis, particularly when
metastasis is diagnosed for the first time [3]. The National
Comprehensive Cancer Network (NCCN) Panel recom-
mended doing a biopsy to confirm recurrence, and repeat-
ing ER/PR and HER2 at the metastatic site [2].
Biopsy results may also be related to survival. In a recent
Swedish trial, it was concluded that patients with tumor
loss of ER or PR during progression have worse survival
than patients with retained receptor expression [8]. How-
ever, in another retrospective trial, no significant survival
difference between patients with discordant versus non-
discordant receptors in MBC was seen [9]. Lastly, Curtit
et al. reported that patients who had undergone biopsy
had survival benefit (median OS 79 months vs 32 months,
p = 0.0001) [10].
However, it is still unclear whether patient characteristics
are associated with having a biopsy and whether having a
biopsy is associated with improved survival. Since prospect-
ive trials to address these questions are not likely to be per-
formed, we conducted a large retrospective trial to help
answer these questions.
Methods
Study design
After approval of the study protocol by the institutional
ethics committee - Helsinki Committee of Rambam
Health Care Campus (RHCC) (Certificate no. 0408-13-
RMB) - a retrospective analysis was conducted of all
medical records of adult patients treated in the Division
of Oncology at RHCC in Haifa, Israel, for metastatic
breast carcinoma from January 2000 to August 2014. Eli-
gibility for the study included having metastatic/locore-
gional non-curable disease, previous treatment for early
breast cancer with curative intent (including surgery),
and an interval of at least 6 months since the end of
adjuvant chemotherapy, radiotherapy, and/or surgery
(adjuvant hormonal therapy was allowed). Excluded
from the study were patients with de novo primary meta-
static disease and patients who were not treated with
curative intent at first diagnosis (without surgery). Pa-
tients were de-identified after data were collected from
digital and non-digital records. Data extracted from the
medical files included demographics and medical history:
age, marital status, number of children, stage (American
Joint Committee on Cancer, 7th edition), grade, ER, PR
and HER2 status (from initial surgery/biopsy specimen),
adjuvant treatment regimen, and type of surgery at ini-
tial diagnosis. Data obtained on patients with suspected
metastases included the sites of metastasis, if and when
a biopsy was done, a pathology report from the biopsy
including documentation of metastatic adenocarcinoma,
ER, PR and HER2status, and date of death or date of last
follow-up. We defined a biopsy as a procedure confirm-
ing adenocarcinoma, including reassessment of HR and
HER2 status. Patients were defined as not having a bi-
opsy if they did not undergo biopsy, had a biopsy which
only histologically confirmed metastases, or did not re-
assess HR and HER2 status. Positive ER or PR expres-
sion was defined as 1% of cells or greater staining for ER
or PR. HER2 assessment was scored from 0–3+. In case
of overexpression scored at 2+, fluorescent in situ
hybridization (FISH) was performed. HER2 was consid-
ered positive if overexpression was scored at 3+ in
immunohistochemistry, or 2+ in immunohistochemistry,
if FISH was positive.
Statistical analysis
Logistic regression was used to calculate the odds ratios
(OR) with 95% confidence intervals (95% CI) and p
values in bivariate analysis to determine associations
between tumor characteristics and likelihood of biopsy.
Based on previous theory [11], variables with p < =0.1
were included in subsequent Multivariable Forward
Stepwise Logistic Regression analysis. The Hosmer-
Lemeshow goodness-of-fit statistic [11] was calculated,
and the area under the receiver operating characteristic
(ROC) curve was used as a measure of model discrim-
ination. Bivariate Cox regression was then used to cal-
culate hazard ratios (HR) with 95% confidence intervals
(CI) and p values for overall survival (OS). Stratified
analysis was used to assess confounding. Variables with
p < =0.1 were used in multivariate Cox Regression ana-
lysis to assess the effect of biopsy on overall survival
(OS), as well as the effect of patient and tumor charac-
teristics. Two-tailed p values of 0.05 or less were con-
sidered statistically significant. Statistical analyses was
performed using SPSS (Statistics Products Solutions
Services) 21.0 software for Windows.
Results
Patient characteristics
The medical records of 409 patients diagnosed with MBC
between 2000 and 2014 were evaluated. Of these 409 pa-
tients, 165 (40%) patients had a biopsy as defined in this
study, while 90 (22%) had only histologic confirmation of
metastases.
Median follow-up for metastatic disease was 30.2 months
(range, 1.1–154.2 months) for all patients and 42.3 months
(range, 1.3–155.8 months) for patients who were alive at
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the time of chart review. Patient characteristics are shown
in Table 1. Median age at metastatic diagnosis was
57.4 years (range, 26.6–88.7 years). Of the 409 patients,
42% were initially diagnosed with stage 0-IIA tumors and
57% with stage IIB-III tumors. Also at initial diagnosis, 186
(45%) patients had grade 1–2 tumors, 146 (36%) had grade
3 tumors (19% data missing), 282 (69%) were HR positive
and 92 (22%) were HER2 positive.
All patients underwent surgery with curative intent.
More than 75% of the patients received chemotherapy
(72% anthracycline-based), either as adjuvant or neoad-
juvant treatment. Adjuvant trastuzumab was given to
only 8% of patients. Adjuvant hormonal therapy was
given to 62% of patients. Biopsy sites were: locoregional
recurrence (skin, chest wall, breast or lymph nodes
(LN)) 77 (47%), bone 33 (20%), liver 26 (16%), lung 14
(8%), abdomen 5, other sites 10.
Clinical characteristics associated with biopsy
Clinical characteristics found to be significantly associated
with having a biopsy are shown in Table 1. Overall, the
percentage of patients who underwent biopsy significantly
increased between 2000 and 2014. Factors related to hav-
ing a biopsy included: not having HR or HER 2 status at
initial diagnosis (OR = 5.96, p < 0.0001), disease-free inter-
val longer than > =3 years (OR = 5.42, p < 0.0001), and
locally advanced disease (in the breast, LN, skin, or chest
wall) (OR = 3.06, p < 0.0001). Advanced stages IIB-III
(OR = 0.40, p < 0.0001) and high grade (grade 3 com-
pared to grade 1 (OR = 0.28, p = 0.026)) were associ-
ated with fewer biopsies. Of note, patient age at time
of suspected metastases was not associated with the
biopsy decision.
In multivariate analysis (Table 2), variables that
remained significantly associated with biopsy were: year of
recurrence (OR = 10.67, p < 0.0001 for 2010–2014),
disease-free interval of > =3 years (OR = 3.20, p < 0.001),
stage 0-IIA (OR = 1.89, p = 0.012), locally advanced disease
(OR = 1.90, p = 0.011), HR+/HER2- at initial diagnosis
(OR = 2.83, p = 0.021), and unknown HR or HER2 at ini-
tial diagnosis (OR = 6.78, p < 0.001).
Discordance in hormone receptor and HER2 status among
primary and metastatic tumors
In 179 patients whose tumor HR status was evaluated
both at primary diagnosis and upon recurrence, HR
status changed from positive to negative in 27 (15%) pa-
tients, and from negative to positive in 14 (8%) patients.
HER2 status was evaluated in 114 patients at both diag-
nosis and recurrence. HER2 changed from positive to
negative in 5 (4%) patients, and from negative to positive
in 10 (9%) patients. Figure 1 describes changes from ini-
tial pathology to biopsy in 107 patients whose HR and
HER2 were measured in both biopsies.
Factors associated with overall mortality
In bivariate analysis, clinical characteristics associated
with overall mortality are summarized in Table 1. At
diagnosis, advanced stage (IIB, III), higher grade (grade
3), and having a triple negative or HR-/HER2+ tumor
was associated with worse survival. In turn, at the time
of metastases, age > =70 years, a disease-free interval of
<3 years, multiple metastatic sites, brain, liver and lung
metastases, or having triple negative disease was asso-
ciated with worse survival. Of note, having a biopsy
upon recurrence was associated with longer survival
(HR = 0.64, p < 0.0001).
Multivariate analysis of factors associated with short-
ened overall survival at initial diagnosis (Table 3) included
advanced stage (stage IIB-III) (HR = 1.40, p = 0.004), triple
negative phenotype (HR = 2.14, p = 0.001), and HR
+/HER2- phenotype (HR = 1.61, p = 0.013). At the time of
metastases, age ≥70 years (HR = 1.65, p = 0.002), and brain
or liver and lung metastasis (HR = 2.85, HR = 2.46, re-
spectively, p < 0.001) were associated with shortened over-
all survival. As in bivariate analysis, not having a biopsy
was associated with shorter survival as compared to hav-
ing a biopsy (HR = 0.67, p = 0.002).
Association of overall survival and biopsy in selected
subgroups
Exploratory analysis of the interaction of biopsy and sur-
vival was performed in selected subgroups (Table 4). A
significant survival benefit was found in patients with
missing data on receptor status (p = 0.001) at the initial
diagnosis, no metastasis in liver and lung or brain (p =
0.001), or younger than age 70 (p = 0.0001). There was
no significant effect on survival among different tumor
phenotypes; however, this might be due to the small
number of patients in each group.
Discussion
The primary purposes in doing a biopsy when MBC is
suspected are to confirm the diagnosis of metastasis and
to reassess HR and HER2 status, two key factors that in-
fluence subsequent treatment. In a prospective trial that
included 64 women with a history of prior breast cancer
and suspected new metastases, a non-breast cancer diag-
nosis was found in 14, and 10% had benign findings
[12]. Of the 205 patients prospectively included in the
BRITS trial, 9% did not have recurrent disease on biopsy
[13]. In our study, 33% of patients had a biopsy only for
histological confirmation of MBC. We also found that,
in recent years, physicians ordered significantly more bi-
opsies (OR = 10.67, p < 0.0001 for 2010–2014), perhaps
due to the fact that recent studies have emphasized that
receptor status can change [10, 14].
The main purpose of a biopsy is to reassess the HR
and HER2 status of the metastatic disease. In our study,
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a biopsy that included confirmation of HR and HER2
status was associated with a significant survival benefit
(p = 0.001). In a study by Amir et al. [14], there were dis-
cordant findings between findings at initial diagnosis
and findings after metastasis in 37.6% of patients, result-
ing in a treatment change in 14% of patients. However,
no change in OS was noted between concordant and
discordant groups in that study [14]. Different results
were seen in a study in China, which showed worse OS
for patients who had receptors discordance in the biopsy
[15]. However, in a review of 13 recent major studies
regarding biopsy in MBC, the impact of this procedure
on survival was not clear [16].
Improved survival for patients whose metastases
retained ER or PR expression as compared to those with
loss of ER or PR expression was shown by Karlsson et al.
in a cohort of 177 patients with MBC [8], and in a
pooled analysis of two prospective studies (BRITS and
DESTINY studies) that included 289 MBC patients,
where a gain of HR or HER2 expression led to most
changes in treatment approaches [17]. We demonstrated
that a biopsy that included confirmation of HR and
Fig. 1 Discordance between initial histology and biopsy (n = 107)
Table 2 Multivariate analysis : Factors predictive of biopsy
Variable P value Adjusted OR (95.0% CI for OR)
Years of metastatic recurrence 2000–04 Ref.
2005–09 .000 3.79 (1.94–7.40)
2010–14 .000 10.67 (5.13–22.22)
Time to recurrence(years) <3 years Ref.
> = 3 years .000 3.20 (1.78–5.76)
Stage at initial diagnosis Stage IIB-III Ref.
Stage 0- IIA .012 1.89 (1.15–3.10)
Site of metastasis at recurrence No locally advanced disease Ref.
Locally advanced disease .011 1.90 (1.16–3.10)
HR &HER2 at initial diagnosis HR+/HER2+ Ref.
HR-/HER2- .349 1.68 (0.57–4.93)
HR-/HER2+ .813 1.15 (0.35–3.74)
HR+/HER2- .021 2.83 (1.17–6.83)
Missing HR or/and HER2 .000 6.78 (2.49–18.45)
All other variables were not significant
HR hormone receptors, HER2 human epidermal growth factor receptor 2
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HER2 was associated with lower mortality. However, the
major benefit was seen mainly in patients who had missing
data on HR or HER2 status at initial diagnosis (p = 0.001).
We offer some explanations for the association of
undergoing biopsy and improved survival: biopsy may
show discordance with initial findings that may be associ-
ated with improved treatment selection, in turn, resulting
in a higher response rate, longer progression free interval,
and possibly improved survival. This explanation is sup-
ported by recent data showing that molecular subtyping
and gene modules of post-relapse biopsy are associated
with survival [18]. In our study, 8% of patients who were
initially HR- became HR+, suggesting that endocrine ther-
apy should be considered. At the same time, 15% of
patients who were HR+ at diagnosis became HR- at biopsy
and would likely not have benefitted from endocrine ther-
apy; for these patients, chemotherapy would be a better
choice. In 9% of patients, HER2- changed to HER2+, a
change that can modify the treatment plan to include
anti-HER2 directed therapy; anti-HER2 directed therapies
significantly improved survival for patients with HER2+
MBC [19, 20]. Of note, a small group, 4% of patients,
changed from HER2+ to HER2- and most likely would
not have benefitted from anti-HER2 therapy. Another
possible explanation for what we observed in our sample
is that physicians choose to biopsy patients whose clinical
scenarios are associated with improved survival, such as
stage at initial presentation and longer disease-free inter-
vals (Table 2). To test this scenario, a prospective random-
ized control trial would be needed.
Although no difference was found in biopsy percent-
ages by age groups, patients <70 years who had a biopsy
were found to have improved survival in subgroup ana-
lysis (p < 0.0001). This finding might be partially due to
competing causes of mortality in older patients and the
fact that older patients are more likely to have HR+ tu-
mors and HR+ metastases [21]. In a large study with a
long follow-up period (28 years), 30% of metastatic
breast cancer patients >70 years died from non-breast
cancer causes [22].
Our study has several limitations. First, it is retrospective
and we assume but cannot be certain that experienced cli-
nicians chose to biopsy patients with suspected metastases
with a more favorable prognosis. Second, we do not have
data on how treatment decisions were affected in patients
with discordant biopsy findings. Third, our study was not
sufficiently powered to check discordance of HR and
HER2 for different metastatic sites. In one study that ex-
amined discordance in 233 distant breast cancer metasta-
ses at different sites (76 skin, 63 liver, 43 lung, 44 brain, 7
gastro-intestinal), receptor conversion seemed to occur
mostly in liver and brain metastases; however, this was sig-
nificant only for PR conversion [23].
Conclusions
Our data confirm the high discordance rate between
findings at initial breast cancer diagnosis and findings at
metastases. Our findings suggest that patients most
likely to benefit from biopsy are those without liver, lung
or brain metastases, are younger than 70 years of age,
and with missing receptors status at initial diagnosis. Re-
cent American Society of Clinical Oncology (ASCO)
guidelines [24] suggest that, in patients with accessible
metastases, biopsy for confirmation of metastases and
Table 3 Multivariate analysis: Factors predictive of All Cause mortality
Variable P value HR Adjusted(95.0% CI for HR)
HR & HER2 at initial diagnosis HR+/HER2+ Ref.
HR-/HER2- .002 2.14 (1.36–3.39)
HR-/HER2+ .179 1.36 (0.86–2.27)
HR+/HER2- .013 1.61 (1.11–2.29
HR and/or HER2 missing .065 1.49 (0.98–2.21)
Site of metastasis at recurrence No brain, liver or lung metastasis Ref.
Liver & lung involvement .000 2.46 (1.68–3.60)
Brain involvement .000 2.85 (1.88–4.31)
Age at metastatic recurrence (years) <70 Ref.
> = 70 .002 1.64 (1.19–2.24)
Stage at initial diagnosis Stage 0-IIA Ref.
Stage IIB-III .004 1.40 (1.12–1.76)
Biopsy No biopsy Ref.
Biopsy .002 0.67 (0.52–0.86)
All other variables were not significant
HR hormone receptors, HER2 human epidermal growth factor receptor 2
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retesting of estrogen receptor, progesterone receptor,
and HER2 status should be offered. However, evidence is
lacking to determine whether modifying anticancer ther-
apy on the basis of a change in receptor status influences
clinical outcomes [24]. The ASCO panel consensus was
to preferentially use the ER, PR, and HER2 status of the
metastasis to direct therapy, if supported by the clinical
scenario and the patient’s goals. In addition, tissues from
metastases may be used to assess molecular differences
not limited to receptor level but also to investigate
DNA, RNA, protein and functional pathway levels and
to look for actionable mutations that might allow for
novel new therapies [5, 25]. Our findings support
current recommendations and show that, in selected pa-
tients, a biopsy at metastatic recurrence that included
HR and HER2 status was associated with significantly
reduced mortality.
Abbreviations
CI: Confidence intervals; ER: Estrogen receptor; FISH: Fluorescent in situ
hybridization; HER2: Human epidermal growth factor receptor 2; HR: Hazard
Table 4 Effect of biopsy on survival for selected clinical and pathological variables
No.
Pts.
All Cause Mortality
No. % total P value HR (95%CI)
TOTAL 409 331 80.9
Biopsy at recurrence
Biopsy No Bx 244 222 91.0 1.00
Bx 165 109 66.1 0.000 0.64 (0.51–0.81)
HR & HER2at initial diagnosis
HR+/HER2+ No Bx 38 30 78.9 1.00
Bx 10 6 60.0 0.499 0.74 (0.30–1.79)
HR-/HER2- No Bx 35 33 94.3 1.00
Bx 14 10 71.4 0.236 0.65 (0.32–1.33)
HR-/HER2+ No Bx 35 33 94.3 1.00
Bx 9 5 55.6 0.562 0.75 (0.29–1.98)
HR+/HER2- No Bx 99 90 90.9 1.00
Bx 74 49 66.2 0.097 0.74 (0.52–1.06)
HR and/or HER2 missing No Bx 37 36 97.3 1.00
Bx 58 39 67.2 0.001 0.45 (0.28–0.71)
Site of metastasis at recurrence
No liver & lung or brain metastases No Bx 202 182 90.1 1.00
Bx 139 86 61.9 0.001 0.63 (0.49–0.82)
Liver & lung metastases No Bx 17 15 88.2 1.00
Bx 18 17 94.4 0.539 0.80 (0.39–1.63)
Brain metastases No Bx 25 25 100.0 1.00
Bx 8 6 75.0 0.196 0.55 (0.22–1.36)
Age at metastatic recurrence
Age <70 years No Bx 207 189 91.3 1.00
Bx 141 92 65.2 0.000 0.62 (0.48–0.80)
Age >=70 years No Bx 37 33 89.2 1.00
Bx 24 17 70.8 0.587 0.85 (0.47–1.54)
Stage at initial diagnosis
Stage 0-IIA No Bx 82 71 86.6 1.00
Bx 90 56 62.2 0.025 0.67 (0.47–0.95)
Stage IIB-III No Bx 161 151 93.8 1.00
Bx 71 51 71.8 0.034 0.71 (0.51–0.97)
HR hormone receptors, HER2 human epidermal growth factor receptor 2, Bx biopsy
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ratio; HR: Hormone receptor; MBC: Metastatic breast cancer; OR: Odds ratio;
OS: Overall survival; PR: Progesterone receptor; RHCC: Rambam Health Care
Campus
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